Mika Nishimura Biography and Net Worth

Director of SiBone

Mika Nishimura has nearly 30 years of experience in medical technology, serving in a variety of operational and executive capacities. Ms. Nishimura is currently an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund. She also serves as a board member for Accuray, Inc. (NASDAQ: ARAY), HOYA (Tokyo Stock Exchange Prime: 7741), and as a board advisor to Tristel, plc, a UK public medical device company. From 2016 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical-stage medical device company acquired by Boston Scientific. Previously, she served as Vice President, Commercial Development at Auxogyn, a medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Inc., where she held P&L responsibilities for the emerging markets. Ms. Nishimura has an MBA from Harvard Graduate School of Business Administration and a B.A. in Economics from Yale University.

What is Mika Nishimura's net worth?: The estimated net worth of Mika Nishimura is at least $372.29 thousand as of March 13th, 2024. Nishimura owns 19,350 shares of SiBone stock worth more than $372,294 as of December 5th. This net worth approximation does not reflect any other investments that Nishimura may own. Learn More about Mika Nishimura's net worth.
How do I contact Mika Nishimura?: The corporate mailing address for Nishimura and other SiBone executives is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. SiBone can also be reached via phone at (408) 207-0700 and via email at [email protected]. Learn More on Mika Nishimura's contact information.
Has Mika Nishimura been buying or selling shares of SiBone?: Mika Nishimura has not been actively trading shares of SiBone over the course of the past ninety days. Most recently, Mika Nishimura sold 2,500 shares of the business's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $16.22, for a transaction totalling $40,550.00. Following the completion of the sale, the director now directly owns 19,350 shares of the company's stock, valued at $313,857. Learn More on Mika Nishimura's trading history.
Who are SiBone's active insiders?: SiBone's insider roster includes Jeffrey Dunn (Director), Laura Francis (CEO), John Freund (Director), Jeryl Hilleman (Director), Gregory Hinckley (Director), E Jr (Director), Anshul Maheshwari (CFO), Mika Nishimura (Director), Michael Pisetsky (SVP), and Anthony Recupero (Insider). Learn More on SiBone's active insiders.
Are insiders buying or selling shares of SiBone?: In the last year, insiders at the sold shares 41 times. They sold a total of 278,971 shares worth more than $4,941,347.88. The most recent insider tranaction occured on November, 25th when CFO Anshul Maheshwari sold 100 shares worth more than $2,000.00. Insiders at SiBone own 4.0% of the company. Learn More about insider trades at SiBone.
Information on this page was last updated on 11/25/2025.

Mika Nishimura Insider Trading History at SiBone

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/13/2024	Sell	2,500	$16.22	$40,550.00	19,350

Mika Nishimura Buying and Selling Activity at SiBone

SiBone Company Overview

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Today's Range

Now: $19.24

$18.99

$19.61

50 Day Range

MA: $16.42

$14.05

$19.67

2 Week Range

Now: $19.24

$12.49

$20.05

Volume

532,706 shs

Average Volume

708,957 shs

Market Capitalization

$834.82 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76